Get the full list », You’re viewing 1 of 12 board members. Im Gegensatz zu einem Firmenprofil, welches ausschließlich beschreibende Informationen enthält, erhalten Sie mit einer Bonitätsauskunft eine Bewertung und Einschätzung der Kreditwürdigkeit. Ganymed Pharmaceuticals GmbH, Mainz, Germany, District Court of Mainz HRB 47318: Earnings, Public funding, Revenue, Employees, Network, Financial information IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. Prior to that, she was chief scientific officer (CSO) from 2001 to 2008. Prof. Sahin ist Mitgründer von TRON und fungierte von 2010 bis 2019 als Geschäftsführer. Die Ganymed Brasserie befindet sich direkt an der Spree mit einem fantastischen Blick zum Fernsehturm, eingebettet zwischen Museumsinsel und Brandenburger Tor. Personalize which data points you want to see and create visualizations instantly. Its majority shareholder is ATS Beteiligungsverwaltung GmbH. … [16], Before founding Ganymed Pharmaceuticals in 2001, Türeci and her husband worked primarily in research and teaching. GANYMED Pharmaceuticals AG is a biotechnology company based out of 12Freiligrathstraße, Mainz, Rhineland-Palatinate, Germany. Auf LinkedIn können Sie sich das vollständige Profil ansehen und mehr über die Kontakte von Özlem Türeci und Jobs bei ähnlichen Unternehmen erfahren. Founded in 2008 . Resources. Frühere Anschriften: 1. [24] She led the company from 2008 to 2016 in the role of Chief Executive Officer (CEO) until the acquisition. Bonitätsauskunft Ganymed Pharmaceuticals GmbH Eine Bonitätsauskunft gibt Ihnen Auskunft über die Zahlungsfähigkeit und Kreditwürdigkeit. Amtliche Dokumente sofort per E-Mail: Liste der Gesell­schafter Amtlicher Nachweis der Eigentums­verhältnisse € 8,50: In den Warenkorb. Türeci met her future husband, Uğur Şahin, while he was working at Saarland University Hospital in Homburg, where she was completing her final year of studies. Ganymed Pharmaceuticals - Crunchbase Company Profile & Funding Dr Sahin has participated in founding GANYMED Pharmaceuticals AG, and co-developed the SEREX (used in screening for novel tumor antigens) and MicroGATE™ technologies. BioNTech. Anonyme Erfahrungsberichte zu Gehalt, Kultur und Karriere von Mitarbeitern und Bewerbern findest Du hier. [27] From 2009 to 2018, she served as chair of the company's scientific advisory board. He also co-founded the biopharmaceutical companies Ganymed Pharmaceuticals and BioNTech and serves on both of their boards. Seit 2014 hält er eine W3-Professur am Universitätsklinikum Mainz. with over 25 years of experience in cancer research and immuno-oncology, specifically in the identification of immunotherapeutic drug targets and the development of antibodies, as well as vaccine-based therapies. 10 Erfahrungsberichte von Mitarbeitern liefern dir die Antwort. Ganymed Pharmaceuticals AG is a biopharmaceutical company developing a new class of immunotherapeutic cancer drugs called Ideal Monoclonal Antibodies (IMABs). Chandler. They sold the firm in 2016 for €422 million ($502 million). Ihr derzeitiger Status ist "eingetragen". Er ist seit 2006 Professor für experimentelle Onkologie an der III. Neil Kumar, Ph.D., is a co-founder and has served as our Chief Executive Officer and a member of our board of directors since April 2015. Die japanische Astella Pharma Inc. übernimmt die in Mainz ansässige Ganymed Pharmaceuticel AG. Özlem was the co-founder of Ganymed Pharmaceuticals AG, a clinical stage biotech company developing unique high-precision antibodies against various solid cancers that was sold to Astellas Pharma Inc. for EUR 422 million in 2016. Get the full list », Co-Founder, Chief Executive Officer & Chief Medical Officer, Co-Founder, Chief Operating Officer & Chief Financial Officer, Co-Founder, Vice Chairman and Deputy Chairman Supervisory Board. Mögliche Einsatzzwecke einer Firmen-Bonitätsauskunft sind: Starting in 2000, Sahin and Türeci had together been leading a research group at University of Mainz. Co-founder of Ganymed Pharmaceuticals Biography She is an M.D. Türeci co-founded and has served as chair of the German Top Research Cluster for Individualized Immune Intervention Ci3 of the German Federal Ministry of Education and Research since 2011 and president of the Association for Cancer Immunotherapy (CIMT), the largest European association for cancer immunotherapy, since 2019. [11] The couple married In 2002; they have a daughter together. [8] Before studying medicine, she hoped to become a nun.[1]. Additional Positions. Founders Erik Karrer; Operating Status Active; Last Funding Type Grant; Also Known As アステラス製薬; Legal Name Astellas Pharma Inc. Stock Symbol OTCPINK:ALPMY ; Company Type For Profit; Number of Exits 3; Phone Number (813) 324-4300 Co-founder and CEO. Türeci and her family continue to live in a modest apartment. R. Mitnacht-Kraus: Employee of Ganymed Pharmaceuticals AG, a company of Astellas Pharma, Inc. [25], In 2008, Türeci was one of the founders, along with her husband Uğur Şahin, of the Mainz-based biotechnology company BioNTech,[26] of which she has been Chief Medical Officer (CMO) since 2018. Recognizing their global resources, I am … … Ist GANYMED Pharmaceuticals AG der richtige Arbeitgeber für Dich? All rights reserved. The company is building a pipeline of antibody therapeutics targeting solid cancers with medical need and large-market potential. They cycle to work and do not own a car. Özlem is co-founder of TRON and was founder and Chief Executive Officer of Ganymed Pharmaceuticals AG, now a subsidiary of Astellas Pharma Inc. She was also central in the founding of BioNTech SE, where she now serves as chairperson of the scientific and clinical advisory board and Chief Medical Officer. [12] Türeci and her husband are[update] billionaires: they sold Ganymed Pharmaceuticals in 2016 for $1.4 billion, and after its 2019 IPO BioNTech was valued over $21 billion in November 2020. [26], Türeci is involved in more than 500 patents filed with her company and partners. [1], Türeci was a staff member of the University Medical Center Mainz [de] in the special research area of immunology there. Nicole Pilch. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently … Prof. Huber earned his MD at the University of Innsbruck. Description. Founder of BioNTech SE, Ganymed Pharmaceuticals AG, Ci3 Management UG and TRON - Translationale Onkologie an der Universitätsmedizin der, Ugur Sahin currently is Chief Executive Officer for BioNTech SE and Managing Director at reBOOST Management GmbH (a subsidiary of BioNTech SE) and Managing Director at Medine GmbH. Dr Türeci was chief executive and Dr Sahin was in charge of research. Die Ganymed Pharmaceuticals AG kann über das Ende des Mietvertrages in 2007 hinaus ihren Standort in Mainz im "Biotechnikum an der Goldgrube" behalten. In 2001, the couple launched the Ganymed Pharmaceuticals biopharmaceutical company to develop immunotherapeutic cancer drugs. Roshini Beenukumar. GANYMED Pharmaceuticals AG gab den Verkauf einer Aktienmehrheit an die ATS bekannt. GANYMED Pharmaceuticals AG | 456 followers on LinkedIn. BioNTech is focused on the development and manufacturing of active immunotherapies for a patient-specific approach to the treatment of cancer and other serious diseases. Ganymed, Sahin’s first company backed by the Struengmanns, was acquired by Japanese pharmaceutical giant Astellas in 2016 for $460 million — plus … Freiligrathstr. Sahin is a professor of oncology at the University of Mainz, Germany, the co-founder of Ganymed Pharmaceuticals with Tureci (developers of cancer immunotherapies), and a recipient of the biennial Iranian prize for Muslims in science and tech, the Mustafa Prize in 2019. Der Mediziner und Krebsforscher wird über die rasche Entwicklung des Impfstoffes und damit einhergehende Herausforderungen sprechen, sowie Möglichkeiten für Innovationen im Bereich der Forschung in Aussicht stellen. Background. From 2018 to April 2019, Prof. Huber served as a member of the supervisory board of TRON. EUR in Ganymed investiert. [26], Using funds from the their successful vaccine, BioNTech plans[update] to pursue its original goal of creating an mRNA-based cancer vaccine; Türeci remarked in March 2021 that the company had several vaccines, with the expectation of offering them to patients within 2 years. He chairs Europe’s Association for Cancer Immunotherapy, is a board member of the Ci3 Cluster of Individualized ImmunIntervention e.V in the Rhine-Main metropolitan area of Germany, and is a senior advisor to international pharmaceutical companies, science-driven SMEs, and big-science institutions. Company profile page for Ganymed Pharmaceuticals AG including stock price, company news, press releases, executives, board members, and contact information Get the full list », You’re viewing 4 of 7 executive team members. Als erstes europäisches Unternehmen hat BioNTech in Kooperation mit Pfizer ein mRNA-basiertes COVID-19- Vakzin entwickelt und Anfang … 21.11.2006 . That firm, Ganymed Pharmaceuticals, was sold to Astellas Pharmaceuticals in 2016 for $460 million (plus an additional $940 million if certain milestones were … Uğur Şahin [uːɾ ʃaː.hin] (* 19. Ganymed Pharmaceuticals. The company is building a pipeline of antibody th, o laboris nisi ut aliquip ex ea commodo consequat. Other investors include Future Capital AG, MIG Fonds, FCPB Gany GmbH, and private individuals. Ganymed Pharmaceuticals AG bleibt in Mainz . They sold the firm in 2016 for €422 million ($502 million). Türeci is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Resarch (AACR), the German Society of Immunology [de], and the German Society of Hematology and Oncology [de]. Auf LinkedIn können Sie sich das vollständige Profil ansehen und mehr über die Kontakte von Özlem Türeci und Jobs bei ähnlichen Unternehmen erfahren. [22] Ganymed and also BioNTech, which was founded later, are spin-offs of the Johannes Gutenberg University Mainz. Get the full list », You’re viewing 5 of 15 investors. Current Position. Developer of antibody therapeutics for the treatment of solid cancers. Özlem was the co-founder of Ganymed Pharmaceuticals AG, a clinical stage biotech company developing unique high-precision antibodies against various solid cancers that was sold to Astellas Pharma Inc. for EUR 422 million in 2016. Sahin war von 2008 bis 2016 Leiter des wissenschaftlichen Beirats der Ganymed Pharmaceuticals AG bis sie von Astellas Pharma Inc. übernommen wurde. [23] This company developed the monoclonal antibody zolbetuximab, which is to be used against esophageal and gastric cancer. Together with her husband Ugur Sahin and her mentor Christoph Huber, they developed the concept of a "translational institute", which was realized in 2001 with the foundation of TRON. Firmenbeschreibung Ganymed Pharmaceuticals GmbH Ganymed Pharmaceuticals GmbH ist eine in Deutschland als Gesellschaft mit beschränkter Haftung registrierte Firma mit der Register-Nr. Im Profil von Özlem Türeci ist 1 Job angegeben. This ... Şahin was one of the founders of the biotechnology company BioNTech, based in Mainz, Germany, in 2008 and has been its CEO ever since. Created with Highcharts 8.1.2 BioNTech BioNTech Ugur Sahin Ugur Sahin Highcharts.com. Dr. Özlem Türeci, CEO and co-founder of Ganymed said, "I am impressed by the competence, commitment and vision of Astellas. Dr Huber is Emeritus Professor of Medicine at the Medical School of the Johannes Gutenberg University in Mainz, co-founder and board member of the Translational Oncology research organization and co-founder and Head of Supervisory Board at the Cluster for individualized immune intervention (CI-3). Mit ihrer ersten Firma "Ganymed" konnten Türeci und Sahin Sponsorengeld einwerben. Her research focuses on the identification and characterization of tumor-specific molecules and the development of immunotherapies against cancer. She is also a Privatdozent at Johannes Gutenberg University in Mainz, Germany. Köln. Huber was a co-founder of Ganymed, now a subsidiary of Astellas Pharma Inc. Abstract 2067. Then, in 2001, they founded Ganymed Pharmaceuticals… Ganymed Pharmaceuticals AG. Im Gegensatz zu gewöhnlichen Unterarmgehhilfen unterstützt die GANYMED® nachweislich das Gangbild. That firm, Ganymed Pharmaceuticals, was sold to Astellas Pharmaceuticals in 2016 for $460 million (plus an additional $940 million if certain milestones were … Ganymed Pharmaceuticals GmbH, Mainz, Germany Dossier Watch Watch. Here are 5 things to know about BioNTech and the married couple behind the COVID-19 vaccine developed with Pfizer Last Updated: Dec. 8, 2020 … Professor Huber is also a co-founder of BioNTech AG and of Ganymed Pharmaceuticals. Recognizing their global resources, I am also confident that Astellas will be able to turn innovative science and promising clinical results into near-term value for patients.”. © 2021 PitchBook Data. September 1965 in İskenderun, Türkei) ist ein deutscher Mediziner. In the 90s, before we started Ganymed, our research team was led by Ugur Sahin – the CEO of BioNTech, and also a co-founder of Ganymed – and me. Tokyo and Mainz, October 28, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Ganymed Pharmaceuticals AG (CEO; Özlem Türeci, “Ganymed”), a biopharmaceutical company located in Mainz, Germany which focuses on the development of antibodies against cancer, announced today that Astellas and Ganymed’s shareholders have entered into an … Er wurde von Zeus geliebt. [15] She is internationally active as a lecturer. [30][1][31] She and her husband decided over breakfast to apply the mRNA vaccine technology they had been researching for two decades to the emerging COVID-19 pandemic,[26] which at the time was spreading in China. XING Mitglieder mit ähnlichen Profilangaben. Contacts Ganymed Pharmaceuticals AG Dr. Luc St-Onge Business Development Anna-Maria Huber. Dr. Michael Koslowski has over 20 years of experience in immunotherapeutic drug discovery and development from positions in academia, biotech and pharmaceutical industry. Dadurch zerstören sie die Tumorzellen, nicht aber das gesunde Gewebe. It also focuses on developing ideal monoclonal antibodies that include cancer-selective targets for maximal high-precision anticancer potency as well as mitigates the threat of toxicity. PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. She studied human medicine at Saarland University in Homburg and received her doctorate from the Medical Faculty of Saarland in 1992. [6] Her mother is a Turkish biologist. This feature is only available to our premium service subscribers. Mainz, Germany. Ob kurz-, längerfristig oder dauerhaft, die GANYMED® Gehhilfen unterstützen in jeder Situation. Co-Founder, Chief Executive Officer & Chief Medical Officer: Tokyo, December 21, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has completed the acquisition of Ganymed Pharmaceuticals AG (“Ganymed”), a biopharmaceutical company located in Mainz, Germany, and Ganymed has become a wholly owned subsidiary of Astellas as of CET December 20, 2016. Die GANYMED® Unterarmgehhilfen bieten eine deutliche Entlastung bei allen Arten von Geh-Beeinträchtigungen. Stage: Public - $595.00M. Dr. Kumar has also served as … Bis 2010 ist nun der Verbleib des Unternehmens am Standort Mainz gesichert. Cornelia Müller. [1], Türeci co-founded and has served as chair of the German Top Research Cluster for Individualized Immune Intervention Ci3 of the German Federal Ministry of Education and Research since 2011[13][14] and president of the Association for Cancer Immunotherapy (CIMT), the largest European association for cancer immunotherapy, since 2019. [19][20] This is a biopharmaceutical research institute that develops new diagnostics and drugs for the therapy of cancer and other diseases with high unmet medical needs. Type: Biotech. Şahin co-founded the company Ganymed Pharmaceuticals in 2001 with his wife, Özlem Türeci. Ganymed is a private company that was founded in 2001 as a spin-off from the Universities of Mainz and Zurich. [2] She was founder and CEO of Ganymed Pharmaceuticals from 2008 to 2016. In 2016, the company was sold to Astellas Pharma and is now a subsidiary. [21], Türeci founded the company Ganymed Pharmaceuticals in 2001 with her later husband Uğur Şahin. BioNTech Co-Founder als Speaker. He is President of CIMT and a board member of Ci3. In 2001 Şahin and his immunologist wife, Özlem Türeci, cofounded Ganymed Pharmaceuticals; Astellas Pharma acquired Ganymed in 2016 for $460 million. [3][4] Türeci and her spouse, Uğur Şahin, became the first Turkish Germans among Germany's top 100 wealthiest people list in 2020. Die Firma wurde vor vier Jahren für mehr als 400 Millionen Euro an ein japanisches Pharmaunternehmen verkauft. If you put a company on your watch list, we'll notify you on your email address when there are new company publications regarding this person. HRB47318 MAINZ. [29], BioNTech has been conducting research on a vaccine against the infectious disease COVID-19 since January 2020[29] in so-called Project Lightspeed[1] under the leadership of Özlem Türeci and Uğur Şahin, who is the company's CEO, making her responsible for the clinical trials area in the development of the vaccine BNT162b2 (the Pfizer–BioNTech COVID‑19 vaccine, sold under the brand name Comirnaty). Wissenschaftlerin. Seine Forschungsschwerpunkte sind die Krebsforschung und die Immunologie. [5], Born in Lastrup, Türeci is the daughter of a Turkish surgeon father from Istanbul, who worked at the Catholic hospital St. Elisabeth-Stift in Lastrup in the district of Cloppenburg. PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach. Duis aute irure, To view Ganymed Pharmaceuticals’s complete valuation and funding history, request access », You’re viewing 5 of 9 competitors. Developer of antibody therapeutics for the treatment of solid cancers. Rheda-Wiedenbrück. 1 Ganymed Pharmaceuticals, AG, 55131 - Mainz/DE; 2 Ganymed Pharmaceuticals, AG, Mainz/DE; 3 Translational Oncology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz/DE More. In fünf Finanzierungsrunden zwischen 2002 und 2013 hatten die Kapitalgeber rund 160 Mio. Ganymed Pharmaceuticals AG is a leading biopharmaceutical company focusing on the development of a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs) for the treatment of solid cancers. Sahin was behind the cooperation between Pfizer and BioNTech on … [28] As CMO, she is primarily responsible for Clinical Research and Development. Ganymed Pharmaceuticals AG, A company of Astellas Pharma, Inc A company of Astellas Pharma Inc Ganymed Pharmaceuticals AG, A company of Astellas Pharma, Inc. Disclosure. München. [1] She co-founded the German biotechnology company BioNTech in 2008, which developed the first approved messenger RNA-based vaccine against COVID-19 in 2020. [10] In 2002, she completed her habilitation at the Johannes Gutenberg University in Mainz in the field of molecular medicine. Molekulare und Angewandte Biotechnologie. Sahin and his wife Tuereci had left their academic careers at the University of Mainz to found Ganymed Pharmaceuticals and work on cancer immunotherapy. GANYMED Pharmaceuticals AG | 422 Follower auf LinkedIn GANYMED Pharmaceuticals AG is a biotechnology company based out of 12Freiligrathstraße, Mainz, Rhineland-Palatinate, Germany. Corporate Name: Ganymed Pharmaceuticals AG (2) Location: Mainz, Germany (3) Representative: Özlem Türeci, CEO (4) Founded year: 2001 (5) Capital Stock: EUR 1,416,308 (as of end of May 2016) (6) Number of employees: 85 (7) Relationship with Astellas: There is no relationship between Astellas and Ganymed required to be disclosed [citation needed]. Ganymed Pharmaceuticals AG is a biopharmaceutical company developing a new class of immunotherapeutic cancer drugs called Ideal Monoclonal Antibodies (IMABs). Erfahre aus erster Hand, ob GANYMED Pharmaceuticals als Arbeitgeber zu dir passt. For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. In 2001, the couple launched the Ganymed Pharmaceuticals biopharmaceutical company to develop immunotherapeutic cancer drugs. According to WSJ, in 2001 the couple set up their first company, Ganymed Pharmaceuticals GmbH, to develop an antibody treatment. [9] She was a habilitation and Heisenberg fellow of the German Research Foundation. Türeci has served as BioNTech's chief medical officer since 2018. Das biopharmazeutische Unternehmen, 2001 als Spin-off der Universitäten Mainz und Zürich gegründet, entwickelt Antikörper zur gezielten Krebstherapie (Ideal Monoclonal Antibodies - IMABs). [1] BioNTech began collaborating on the vaccine with Pfizer in March,[1] and it was approved within 11 months. [17][18] Since 2002, she has been a private lecturer at the University Medical Center Mainz in the field of cancer immunotherapy. Türeci credits their rapid success in part to international collaboration, as BioNTech worked with Chinese firm Fosun Pharma[26] and itself has staff from 60 countries. Senior Scientific Content Writer. Sehen Sie sich das Profil von Özlem Türeci im größten Business-Netzwerk der Welt an. Ganymed Pharmaceuticals Closes EUR 45 Million Financing Round from MIG, Future Capital, FCPB, and ATS Beteiligungsverwaltung . Login. Logg Dich jetzt ein, um das ganze Profil zu sehen. Sehen Sie sich das Profil von Özlem Türeci im größten Business-Netzwerk der Welt an. But academic research was not enough for her, so 16 years ago she started her own company, Ganymed Pharmaceuticals. She is internationally active as a lecturer. Dr. Özlem Türeci, CEO and co-founder of Ganymed said, “I am impressed by the competence, commitment and vision of Astellas. [7] She attended, among others, the Städtisches Gymnasium in Bad Driburg and the Werner-von-Siemens-Gymnasium in Bad Harzburg. Im Profil von Özlem Türeci ist 1 Job angegeben. Astellas übernimmt Ganymed Pharmaceuticals . Der Gang ist aufrechter und die Schultern werden weniger beansprucht. Managing Partner / Publisher. Investors: 11. Die Firma wurde 22.03.2017 registriert. Astellas Pharma plans to acquire Ganymed Pharmaceuticals for up to €1.282 billion ($1.4 billion), in a deal intended to expand the buyer’s oncology portfolio, the companies said today. Forschungsschwerpunkte: GANYMED Pharmaceuticals AG ist ein führendes biopharmazeutisches Unternehmen, das hoch tumorspezifische Antikörperwirkstoffe gegen neue Zielstrukturen zur gezielten Behandlung solider Tumore entwickelt.Das Unternehmen verfügt über eine der leistungsstärksten integrierten Komplettlösungen im Bereich der Antikörpertherapeutika, von der Identifizierung … He is a member of numerous scientific committees, in particular the international Association of Cancer Immunotherapy (CIMT), which he co-founded and chairs. Im Herzen Berlins kommen Sie in den Genuss authentischer französischer Küche und kulinarischer Spezialitäten. PitchBook is a financial technology company that provides data on the capital markets. Ganymed Pharmaceuticals AG An der Goldgrube 12 55131 Mainz. Özlem Türeci (Turkish pronunciation: [ˈœzlæm ˈtyredʒi]; born 6 March 1967) is a German physician, scientist and entrepreneur. 12, 55131 Mainz. ", "Deutscher Nachhaltigkeitspreis: Startseite", "FT People of the Year: BioNTech's Ugur Sahin and Ozlem Tureci", "Axel Springer Award 2021 geht an Biontech-Gründer", https://en.wikipedia.org/w/index.php?title=Özlem_Türeci&oldid=1017150032, Johannes Gutenberg University Mainz faculty, Knights Commander of the Order of Merit of the Federal Republic of Germany, Pages containing links to subscription-only content, All Wikipedia articles written in American English, Articles containing potentially dated statements from November 2020, All articles containing potentially dated statements, Articles containing potentially dated statements from March 2021, Articles with unsourced statements from January 2021, Wikipedia articles with ORCID identifiers, Wikipedia articles with WorldCat-VIAF identifiers, Creative Commons Attribution-ShareAlike License, German Society for Hematology and Oncology, 1997: Calogero Paglierello Research Award, This page was last edited on 11 April 2021, at 03:26. Mythos. Astellas Pharma plans to acquire Ganymed Pharmaceuticals for up to €1.282 billion ($1.4 billion), in a deal intended to expand the buyer’s oncology portfolio, the companies said today.